Cover Image
市場調查報告書

關注市場分析:大腸激躁症 (IBS)

Market Spotlight: Irritable Bowel Syndrome (IBS)

出版商 Datamonitor Healthcare 商品編碼 594579
出版日期 內容資訊 英文 40 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
關注市場分析:大腸激躁症 (IBS) Market Spotlight: Irritable Bowel Syndrome (IBS)
出版日期: 2017年11月01日 內容資訊: 英文 40 Pages
簡介

本報告提供過敏性腸道症候群 (IBS)的治療藥市場相關分析,疾病概要和患者數的變化、預測,目前的主要的治療方法,法規環境和近幾年主要的事件,現在開發中臨床實驗的進展與上市計劃,主要的治療藥的市場趨勢預測 (今後10年份),資本交易的動向等調查。

分析的要點

疾病的背景情況

  • IBS的亞型

治療方法

  • 緩瀉劑
  • 止瀉藥
  • 解痙藥
  • 抗憂鬱劑
  • 血清素受體激動劑
  • 氯離子通道活化劑
  • 鳥糞嘌呤環化酶致效劑
  • 抗生素
  • 類鴉片物質受體
  • 益生菌

流行病學

已上市醫藥品

  • 各國的認證情形

開發平台上的醫藥品

將產生的主要事件

法規相關的主要的事件 (1件)

授權合約、資產收購交易

母體專利

商機

臨床實驗形勢

  • 贊助商數:各狀態
  • 贊助商數:各相位

相關分析

  • 處方藥的資訊

附錄

目錄
Product Code: DMKC0181355

This Market Spotlight report covers the irritable bowel syndrome (IBS) market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

  • Datamonitor Healthcare estimates that in 2016, there were approximately 754 million prevalent cases of irritable bowel syndrome (IBS) in those aged 15 years and over worldwide, and forecasts that number to increase to 830 million prevalent cases by 2025. The approved drugs in the IBS space target chloride channel 2, calcium channel, serotonin 5-HT3 receptor, guanylyl cyclase C receptor, opioid receptor, and RNA polymerase. These drugs are administered via the oral route.
  • Therapies in mid- and late-stage development for IBS focus on a wide variety of targets. Among these therapies, Trulance (plecanatide; Synergy), a guanylyl cyclase C receptor agonist, is closest to market for IBS, with a supplementary New Drug Application (sNDA) filing. All the pipeline drugs in mid- to late-stage development for IBS are administered via the oral route.
  • High-impact upcoming events for drugs in the IBS space include topline Phase II and Phase III trial results and a Prescription Drug User Fee Act (PDUFA) date for Trulance's sNDA.
  • There were 16 licensing and asset acquisition activities involving IBS drugs during 2012-17. The largest deal during that time was the $2,905m research, development, collaboration, and license agreement in January 2017 between Allergan and Assembly Biosciences, for the worldwide rights to Assembly's microbiome gastrointestinal (GI) development programs.
  • Xifaxan's (rifaximin) sales ranked highest during 2012-16, although the majority of its sales were for indications other than IBS. However, during 2017-22, Linzess (linaclotide acetate) is forecasted to have the highest revenues.
  • The clinical trials distribution across Phases I-IV indicates that the majority of trials for IBS are in early and mid-phases of development, with 65.4% of trials in Phase I-II, and only 34.5% in Phase III-IV.
  • The US has a substantial lead in the number of IBS clinical trials globally. The UK leads the five major EU markets (France, Germany, Italy, Spain, and the UK), while Japan has the top spot in Asia.
  • Clinical trial activity in the IBS space is dominated by completed trials. GlaxoSmithKline, Novartis, and Allergan have the highest number of completed clinical trials for IBS, with 36, 33, and 31, respectively.
  • Allergan leads industry sponsors with the highest number of clinical trials for IBS, followed by GlaxoSmithKline and Novartis.

TABLE OF CONTENTS

KEY TAKEAWAYS

DISEASE BACKGROUND

  • IBS subtypes

TREATMENT

  • Laxatives
  • Antidiarrheal drugs
  • Antispasmodics
  • Antidepressants
  • Serotonin receptor agonists
  • Chloride channel activator
  • Guanylyl cyclase C agonists
  • Antibiotics
  • Opioid receptors
  • Probiotics

EPIDEMIOLOGY

MARKETED DRUGS

  • Approvals by country

PIPELINE DRUGS

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Oncology Captures One In Three New EU Drug Approvals In 2016

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information:

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of irritable bowel syndrome, 2016-25
  • Figure 2: Prevalent cases of irritable bowel syndrome, by age, 2016
  • Figure 3: Overview of pipeline drugs for irritable bowel syndrome in the US
  • Figure 4: Pipeline drugs for irritable bowel syndrome, by company
  • Figure 5: Pipeline drugs for irritable bowel syndrome, by drug type
  • Figure 6: Pipeline drugs for irritable bowel syndrome, by classifications
  • Figure 7: Key upcoming events in irritable bowel syndrome
  • Figure 8: Licensing and asset acquisition deals in irritable bowel syndrome, 2012-17
  • Figure 9: Parent patents in irritable bowel syndrome
  • Figure 10: Clinical trials in irritable bowel syndrome
  • Figure 11: Top 10 drugs for clinical trials in irritable bowel syndrome
  • Figure 12: Top 10 companies for clinical trials in irritable bowel syndrome
  • Figure 13: Trial locations in irritable bowel syndrome
  • Figure 14: Irritable bowel syndrome trials status
  • Figure 15: Irritable bowel syndrome trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of irritable bowel syndrome, 2016-25
  • Table 2: Prevalent cases of irritable bowel syndrome, by gender, 2016
  • Table 3: Prevalence of irritable bowel syndrome, by gender, 2016
  • Table 4: Marketed drugs for irritable bowel syndrome
  • Table 5: Approvals by country for irritable bowel syndrome
  • Table 6: Pipeline drugs for irritable bowel syndrome in the US
  • Table 7: Historical global sales, by drug ($m), 2012-16
  • Table 8: Forecasted global sales, by drug ($m), 2017-22
Back to Top